Cargando…

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Methotrexate (MTX) is the central drug in the management of rheumatoid arthritis (RA) and other immune mediated inflammatory diseases. It is widely used either in monotherapy or in association with other synthetic and biologic disease modifying anti-rheumatic drugs (DMARDs). Although comprehensive c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romão, Vasco Crispim, Canhão, Helena, Fonseca, João Eurico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606422/ https://www.ncbi.nlm.nih.gov/pubmed/23343013 http://dx.doi.org/10.1186/1741-7015-11-17

Ejemplares similares

Response measures influence comparative effectiveness of biological drugs in rheumatoid arthritis
por: Canhao, Helena, et al.
Publicado: (2012)

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?
por: Halilova, Karina I., et al.
Publicado: (2012)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Structural and functional genomics in Old World camels—where do we stand and where to go
por: Burger, Pamela A, et al.
Publicado: (2022)

Disease mechanisms in preclinical rheumatoid arthritis: A narrative review
por: Romão, Vasco C., et al.
Publicado: (2022)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review
por: Romão, Vasco C., et al.
Publicado: (2021)

Sexual Abuse in 8-year-old Child: Where Do We Stand Legally?
por: Behere, Prakash Balkrishna, et al.
Publicado: (2013)

Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?
por: Romão, Vasco C., et al.
Publicado: (2019)

Rheumatoid Arthritis and Malignancy: What Should We Do With DMARDs?
por: Jeon, Chan Hong
Publicado: (2022)

Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
por: Németh, Tamás, et al.
Publicado: (2022)

Where Do We Stand?
Publicado: (1891)

Cancer: Where We Stand
Publicado: (1951)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor-κβ expression in monocytes from patients with early rheumatoid arthritis
por: Perpétuo, Inês Pedro, et al.
Publicado: (2017)

COVID-19 in Children: Where do we Stand?
por: Nikolopoulou, Georgia B., et al.
Publicado: (2022)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Therapeutic Intervention in Motor Disorders at Young and Old Age: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2001)

Infections in Biological and Targeted Synthetic Drug Use in Rheumatoid Arthritis: Where do We Stand? A Scoping Review and Meta-analysis
por: Bergmans, Barbara J. M., et al.
Publicado: (2023)

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
por: Romão, Vasco C., et al.
Publicado: (2017)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Where we stand with the real superworld
por: Zichichi, Antonino
Publicado: (1993)

Correcting LEP: where we stand
por: Kleiss, R H
Publicado: (1989)

Recurrent Glioblastoma: Where we stand
por: Roy, Sanjoy, et al.
Publicado: (2015)

Corneal xenotransplantation: Where are we standing?
por: Yoon, Chang Ho, et al.
Publicado: (2021)

Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients
por: Burkard, Theresa, et al.
Publicado: (2021)

THREE-DIMENSIONAL PRINTING IN ORTHOPEDICS: WHERE WE STAND AND WHERE WE ARE HEADING
por: EJNISMAN, LEANDRO, et al.
Publicado: (2021)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
por: Chung, Wei-Hsin, et al.
Publicado: (2023)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

The old and new therapeutic approaches to the treatment of giardiasis: Where are we?
por: Busatti, Haendel GNO, et al.
Publicado: (2009)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
por: Agapidou, Alexandra, et al.
Publicado: (2016)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Application of molecular SERS nanosensors: where we stand and where we are headed towards?
por: Jahn, Izabella J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ves3h5m0vajrd3aklj0cohsic1